贝伐单抗玻璃体腔注射术并发症的临床分析

目的: 观察分析玻璃体腔注射贝伐单抗(bevacizumab)术后并发症的发生率与原因。方法: 随即选择湿性年龄相关性黄斑变性207例207眼,所有病例均行玻璃体腔注射bevacizumab1.5mg/0.06mL。于术后第1d;1,4,12wk除了详细询问主诉,并进行常规视力(最佳矫正视力)、非接触眼压、裂隙灯显微镜、间接眼底镜等检查。结果: 治疗12wk后,视力改善的有效率为90.8%。术后出现眼痛伴异物感7例(3.4%),眼睑皮肤瘙痒1例(0.5%),结膜充血6例(2.9%),球结膜下出血1例(0.5%),术后眼压升高2眼(1.0%)。结论: 玻璃体腔注射bevacizumab的并发症少,安全性高。但需进一步的大样本、随机化、多中心的临床实验,规范该药的临床应用。

Analysis on complications after intravitreal injection of bevacizumab

AIM: To observe and analyze on the incidence rate and causes of complications after anintravitreal injection of bevacizumab.

METHODS: Totally, 207 cases(207 eyes)with wet age-related macular degeneration were selected randomly. All cases were treated with intravitreal injections of bevacizumab(1.5mg/0.06mL)and asked for chief complaints at 1 day, 1 week, 4, 12 weeks after operation, and also examined for routine visual acuity(best corrected visual acuity, BCVA), non-contact tonometer, slit lamp microscope and indirect ophthalmoscope etc.

RESULTS: Among 207 cases(207 eyes), visual acuity improved efficiency was 90.8% 12 weeks after treatment, foreign body sensation was found in 7 cases(3.4%), eyelid skin pruritus in 1 case(0.5%), conjunctival congestion in 6 cases(2.9%), subconjunctival hemorrhage in 1 case(0.5%), post-operative intraocular pressure elevation in 2 cases(1.0%).

CONCLUSION: The intravitreal injection of bevacizumab is effective with fewer complications. We propose to carry out a further randomized multicenter and larger-sample clinical research and further draw up the clinical application criterion of bevacizumab.